Overview of Today

Quick Facts

Property	Description
Active ingredient	Nonoxinol (Nonoxynol-9)
Form	Vaginal suppositories, cream, gel, or film
Pharmacological class	Spermicide (Vaginal contraceptive)
Common use	Prevention of pregnancy (Contraception)
Origin	Synthetic chemical compound

What is Today and What Type of Medicine is It?

Today is a non-hormonal, vaginal contraceptive whose active component is the synthetic chemical compound Nonoxinol (also known as Nonoxynol-9). It belongs to the pharmacological class of spermicides, which are chemical agents used to rapidly destroy or immobilize sperm locally within the vagina. This classification establishes its function as a chemical barrier method for contraception, distinguishing it from methods that work systemically by affecting hormones. Nonoxynol-9 is characterized by its ability to exert a surface-active effect on sperm, which functions by chemically disrupting the structure of sperm cells. The brand Today is specifically recognized for its accessibility as an over-the-counter (OTC) product designed for use just before intercourse, offering an option for those who may have been unable to use other contraceptive methods.

Composition and General Purpose

The pharmaceutical entity is a single-active-ingredient product containing Nonoxinol as the sole agent responsible for its contraceptive action. This preparation is delivered through vaginal administration using various dosage forms, most commonly as vaginal suppositories (ovules), or alternatively as a cream, gel, or film. These forms are specifically formulated with a suitable base designed to release the active ingredient and coat the necessary areas within the vagina. The core therapeutic purpose is contraception, specifically the prevention of pregnancy, through localized action at the site of potential fertilization. This action is clinically recognized for providing immediate, localized, chemical protection. Spermicides are among the various methods available for pregnancy prevention and serve as an option for individuals who require non-hormonal contraceptive choices.

What side effects are possible with Today?

Possible side effects and safety information

The safety profile for Nonoxinol-9 (the active ingredient in Today) is primarily characterized by the risk of local irritation and specific regulatory constraints defined by government health authorities. The documented adverse reactions largely reflect its topical mechanism of action.

Adverse Reactions and Systemic Classification

The most consistently documented adverse reactions are local application site reactions affecting the reproductive and urogenital systems. These may include vaginal burning, itching, rash, or redness (erythema). Regulatory labeling also notes the potential for irritation of the penis in the sexual partner. While precise frequency classifications for these common effects are often not numerically defined across all official sources, they are consistently cited as possible.

A serious, yet rare, adverse reaction documented in regulatory texts is Toxic Shock Syndrome (TSS). This risk is specifically associated with the use of the vaginal sponge formulation of Nonoxinol-9 and is officially classified as a rare event. Severe systemic allergic reactions are also possible and require discontinuation of use.

Critical Safety Restrictions and Population Considerations

The official labeling mandates critical restrictions regarding use and safety limitations:

HIV/STD Warning: Nonoxinol-9 provides no protection against HIV/AIDS or other Sexually Transmitted Diseases (STDs). This is a mandatory warning.
Contraindications: The product is contraindicated for individuals who have HIV/AIDS or who are at high risk for HIV/AIDS, as frequent use may increase the risk of getting or spreading the virus from an infected partner.
Time-Related Pattern: Regulatory documents note that frequent use (defined as more than once per day) can increase local irritation and may increase the risk associated with HIV transmission.
Other Restrictions: Specific product forms, such as the vaginal sponge, carry additional constraints, including contraindication within six weeks after childbirth or for individuals with a known sulfite allergy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information concerning an overdose of the vaginal spermicide Today (Nonoxinol-9) is primarily focused on the potential hazard of accidental oral ingestion. Regulatory documentation does not list specific systemic symptoms resulting from acute overdose via excessive vaginal application, as the product's action is localized.

Overdose Manifestations and Risk Factors

The only circumstance associated with a documented overdose risk is accidental oral ingestion of the product, which is classified as a scenario where harm may occur. No specific systemic manifestations are documented for overdose resulting from the product’s intended route of administration.

When Immediate Medical Help Is Required

The labeling mandates immediate action in cases of suspected overdosage. If Today is swallowed, individuals must get medical help or contact a Poison Control Center right away or contact a poison control center or emergency room at once. This instruction underscores the urgency of seeking professional intervention following ingestion. No specific antidote for Nonoxinol-9 overdose is described in the official regulatory prescribing information. The recommended approach to management is supportive and symptomatic. No specialized considerations are explicitly documented for specific populations in the official overdose section.

Therapeutic Uses of Today

What Today Treats: Main Uses and Benefits

This medication plays a role in managing the risk of conception by providing a chemical barrier at the site of potential fertilization. The active ingredient, Nonoxynol-9, is used to provide support in managing the risk of conception, and its core use is within the therapeutic domain of family planning.

Nonoxinol (Today) is commonly used to help with the need for a non-hormonal birth control method, assisting patients who must avoid symptoms related to systemic imbalance common with hormonal compounds. It is applied in clinical settings where coitus-dependent, on-demand protection is appropriate, or when patients require adjunctive support for reliance on mechanical barriers like a diaphragm or cervical cap.

Quick Fact: Support for Contraceptive Needs This method supports the patient by providing an accessible, localized option for contraception, may assist with managing the risk burden, and may help patients cope more steadily with symptom fluctuations related to reproductive choices.

Regulatory References

NIH MedlinePlus overview of Nonoxynol-9

Eligibility and Restrictions for Use

The eligibility for Today (a combined hormonal medication) is strictly defined by government regulatory documents to minimize specific health risks, particularly venous thromboembolism (VTE).

Contraindications (Prohibited Use)

Use is absolutely prohibited for patients who have known thrombogenic mutations, a history of VTE, stroke, or ischemic heart disease. It is also contraindicated for those with known or suspected breast cancer or severe, uncontrolled hypertension (e.g., systolic ge 160 mmHg). Women age 35 or older who smoke and those with migraine headaches with aura at any age must not use this medicine.

Population-Specific Restrictions

Population Category	Eligibility Status	Specific Limitation
Pregnancy	Contraindicated	Must not be used if pregnant or suspected of being pregnant.
Postpartum	Contraindicated	Prohibited for use less than 21 days postpartum.
Breastfeeding	Not Recommended	Use is restricted, particularly in the first 6 weeks postpartum, due to VTE risk and potential interference with milk supply.
Hepatic Function	Contraindicated	Must not be used in patients with severe cirrhosis or liver tumors.

Eligibility also requires that the medicine be stopped at least four weeks prior to major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

The regulatory documentation for Nonoxinol (Nonoxynol-9) establishes an interaction profile focused on preserving the product's local efficacy rather than systemic pharmacokinetic effects. The official restrictions pertain primarily to co-administration with other substances and materials applied in the vaginal area.

Category	Official Regulatory Information
Medicinal Product Categories	Other intravaginal products, including douches and vaginal yeast infection creams or suppositories.
Mechanistic Basis	Local Efficacy Reduction: Co-administered products may wash away, dilute, or chemically compromise the spermicide, resulting in diminished contraceptive effectiveness.
Timing-Based Rules	Douches: Administration of vaginal cleansing products must be delayed by at least 6 hours after the last act of intercourse to maintain protection.
Material Compatibility	The product may cause latex barrier devices (such as condoms or diaphragms) to weaken or break unless the specific Nonoxinol formulation is labeled as safe for use with latex.

This interaction structure is classified by regulatory authorities as Efficacy-Reducing, highlighting constraints necessary to ensure the expected contraceptive outcome. The constraints strictly apply to the local site of action. Formal documentation of systemic drug-drug interactions, or interactions with food, alcohol, and herbal supplements, is not featured in the primary regulatory warnings for this localized agent. The overall interaction map is defined by procedural and local physical-chemical constraints.

Mechanism of Action

How Today Works: Pharmacodynamic Mechanism

This drug's primary action is centered in the liver, where it exerts competitive inhibition on the enzyme 3-Hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Reductase. This molecular interaction blocks the mevalonate pathway, which is the rate-limiting step for endogenous cholesterol synthesis. The resulting depletion of intracellular cholesterol initiates a cellular feedback cascade. In response, liver cells significantly upregulate the synthesis and surface expression of Low-Density Lipoprotein (LDL) Receptors . This increased receptor density enhances the removal and catabolism of circulating LDL-C and VLDL particles from the bloodstream, leading to a substantial decrease in the systemic circulating lipid load. Separately, the inhibition of the mevalonate pathway reduces the availability of isoprenoid precursors. This change indirectly modulates the function of signaling proteins (G-proteins) within the blood vessel walls, influencing pathways that affect vascular function and local inflammatory activity.

Dosage and Administration Information

How Today is Used

The usage of Today (Nonoxinol/Nonoxynol-9) is characterized by its application as a localized, event-dependent contraceptive. Its administration principles are designed to ensure the active ingredient is properly positioned to function as a chemical barrier.

Official Administration Guidelines

Instruction Domain	General Requirement
Route of Administration	Must be administered via the vaginal route only.
Standard Dosing	One full dose (suppository, film, or applicator-full) must be used before each act of sexual intercourse.
Re-dosing	Re-application of a new, full dose is mandatory for every repeated act of intercourse.
Special Conditions	Must be inserted deep into the vagina to cover the cervix.

Timing and Procedural Steps

Proper use requires specific timing and procedural adherence, which varies by the dosage form:

Waiting Period: A minimum time is required for the formulation to dissolve or disperse (e.g., 10 minutes for some suppositories or 15 minutes for some films) before intercourse begins. This is essential for the product to become effective.
Post-Coital Care: To maintain the localized protective effect, individuals must avoid douching for a minimum of 6 hours following the last act of intercourse.
Population-Specific Rules: Due to the localized action of the spermicide, there are no specific systemic dose adjustments for renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Today (Nonoxinol)

Evidence for Use in Preventing Pregnancy

Research has evaluated Nonoxinol-9 (the active ingredient in Today) primarily through Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews to evaluate its use in the research context of contraception. These studies monitored populations of healthy adult women of reproductive age who was studied for the prevention of pregnancy. Researchers focused on specific outcomes, such as the cumulative chance of pregnancy over set periods of observation.

Findings describe patterns observed in the studies where the measured chance of pregnancy varied across different formulations and among different user groups. Research indicates that outcomes measured in the trials was associated with the level of consistency and correctness of application. Regulatory assessments of this evidence base indicate that the overall contraceptive performance observed in trials may be documented as lower than that reported for hormonal or long-acting reversible contraceptive methods.

Research on Nonoxinol-9's Use with Barrier Methods

Studies have also explored Nonoxinol-9’s use in a research context involving fluctuating or unstable symptoms when applied as an adjunctive component alongside mechanical devices, such as the diaphragm or cervical cap. These trials examined the combined rate of conception compared to the barrier method used alone. The research examined whether the spermicide's inclusion was associated with differences in the rate of conception. Research so far suggests that the incremental contribution of the spermicide to the overall efficacy of the barrier device is difficult to precisely isolate and quantify.

Research on Nonoxinol-9 for Preventing STIs (Important Context)

Large-scale Randomized Controlled Trials (RCTs) have been conducted specifically to evaluate whether Nonoxinol-9 may play a role in preventing the acquisition of Sexually Transmitted Infections (STIs), including HIV. These studies monitored new diagnoses of infections.

Multiple large RCTs observed that no reduction in the acquisition of HIV or other STIs was observed in the Nonoxinol-9 groups compared to control groups. Additionally, a pattern was observed in some studies where frequent use was associated with an increased incidence of genital lesions (epithelial disruption). Regulatory bodies rely on this evidence base to clarify that Nonoxinol-9 is not supported for use as a method for STI prevention.

Frequently Asked Questions (FAQ)

Common questions about Today (FAQ)

Q: How does Today differ from other common medicines used for the same condition?

Today is classified as a spermicide, which is a localized, non-hormonal chemical barrier method of contraception. Its active ingredient works by damaging sperm cells right where they are applied. This is different from systemic methods, such as hormonal birth control, which prevent pregnancy by affecting a person's hormone levels or ovulation.

Q: How long does Today usually stay in a person's system after they stop taking it?

Official information indicates that very little of the active ingredient is absorbed into the bloodstream. Today is primarily designed for local action and is not intended to have significant systemic effects. To maintain the product's intended local efficacy, regulatory guidelines advise avoiding douching for at least six hours following the last use.

Q: What population groups are specifically described as eligible to use Today in official documents?

This product is an over-the-counter (OTC) vaginal contraceptive intended for use by females of reproductive potential for the purpose of preventing pregnancy. Official labeling includes a critical restriction that the product is contraindicated, or prohibited, for use by individuals who have HIV/AIDS or are at high risk for HIV/AIDS.

Q: Are the reported side effects for Today generally mild or severe?

The most commonly reported adverse reactions are generally localized, such as burning, itching, or rash at the application site. However, official warnings note a rare but serious risk called Toxic Shock Syndrome (TSS), which is primarily associated with the sponge formulation.

Q: What is the expected long-term outcome or general expectation when using Today?

When used correctly, the expected outcome is prevention of pregnancy, though efficacy rates can vary. Official warnings highlight that using the product too frequently, defined as more than once per day, can increase local irritation. This irritation is noted as potentially increasing the risk of contracting HIV/AIDS or other sexually transmitted diseases from an infected partner.

Q: What if I am already taking a medicine that has a known interaction with Today?

The primary interactions described in official labeling involve local products, such as other vaginal products, douches, or lubricants, and materials like latex. These substances can potentially diminish the product's effectiveness. Official warnings advise against using products that might compromise the spermicide's ability to work as intended.

Q: What is the consensus in research about the long-term use of Today?

Studies examined by regulatory bodies indicate that high-frequency use of this product, specifically more than once per day, has been associated with an increased incidence of genital irritation. Due to this potential for irritation and lesions, official sources state this use pattern may increase the risk of getting or spreading HIV/AIDS or other STDs.

Q: Why is Today not recommended for people with a specific pre-existing condition?

Official product information strictly prohibits use by individuals with or at high risk for HIV/AIDS. This is because research suggests that frequent use of the spermicide may cause irritation that could increase the risk of the virus being acquired from an infected partner.

Q: Are there any known drug-disease interactions mentioned in the official labeling for Today?

Yes, regulatory information explicitly states the product is contraindicated for individuals with or at high risk for HIV/AIDS. Additionally, specific product formulations, such as the vaginal sponge, carry restrictions for those with a known sulfite allergy.

Q: Why do official documents mention that Today should be used with caution in certain patients?

Official labeling contains specific warnings and contraindications. The product is strictly for vaginal use and does not protect against STDs. The primary warning is against use by people with or at high risk for HIV/AIDS due to the potential for increased risk of infection.

Q: Do children or teenagers ever use Today?

Today is intended for use by females of reproductive potential. Dosing recommendations provided by regulatory sources generally refer to the dosing used in adults and post-menarche adolescents. The product is not intended for use by children before the onset of menstruation.

Q: Is there any information about Today's use during pregnancy or breastfeeding?

Official labeling advises against using the product if pregnancy is confirmed or suspected. Regarding breastfeeding, limited data reviewed by the NIH suggests that use of the product is generally considered acceptable and is not expected to cause adverse effects in breastfed infants.

Q: What if I experience a rare or unexpected side effect while on Today?

Official labeling advises that if you or your partner experience unusual irritation, such as burning, itching, or a rash, or if there is a suspicion of a severe reaction like Toxic Shock Syndrome (TSS), official guidance advises seeking medical attention or contacting a healthcare provider if severe or unexpected effects occur.

Q: Why does the packaging for Today have a black box warning?

Official regulations require the product to carry a prominent Sexually Transmitted Disease (STD) alert, often displayed in a bold manner. This is a critical warning stating that the product does not protect against HIV/AIDS or other STDs and that its frequent use may increase the risk of acquiring HIV from an infected partner.

Q: Are there any documented cases of overdose with Today, and what are the signs?

The product is strictly for vaginal application. Regulatory documents advise that if the product is accidentally swallowed, one should immediately seek medical help or contact a Poison Control Center.

Q: What is the general safety classification of Today according to regulatory agencies?

Today is classified by the FDA as an Over-The-Counter (OTC) drug, meaning it is available without a prescription. Its overall safety profile is defined by the risk of local irritation and the mandated warning that it provides no protection against HIV/AIDS or other STDs.

Q: Is Today safe for older adults (geriatric population)?

Official product information specifies that Today is intended for use in women of reproductive potential. Regulatory information does not typically include a specific review for safety in the postmenopausal or geriatric population for this type of localized, event-dependent contraceptive.

Q: Are there any studies comparing the effects of Today in men versus women?

While the product is intended for use by women, official labeling notes that adverse reactions may extend to the sexual partner. The documented warning specifically mentions the potential for irritation of the penis in the sexual partner.

Q: How is Today typically packaged?

Regulatory product information shows that the product is sold in its original container, such as a box containing films, suppositories, or an applicator tube of gel. All packaging includes a package insert which provides complete directions for use and official warnings.

Q: Is Today only for adults, or is it approved for pediatric use?

The product is intended for use in females who are of reproductive potential. Dosing is referenced for adolescents who have started menstruating (post-menarche), but the product is not approved for use in children before the onset of menstruation.

How should Today be stored and disposed of?

How to Store and Dispose of Today (Nonoxynol-9)

The storage and disposal instructions for Today vaginal contraceptives are based on official regulatory labeling to ensure product stability.

Official Storage Requirements

Requirement Type	Condition
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Heat Protection	Must be protected from excessive heat; do not store above 30 C (86 F).
Container Rule	Must be kept in the original container.
Child Safety	Store out of the reach of children.

The official storage profile mandates maintaining the product within the specified temperature range to prevent degradation. For disposal, any unused or expired product must be discarded in accordance with local requirements for pharmaceutical waste.

Today